Evidence map›Paper›PMID 40681176›Full record

ArticleJournal for immunotherapy of cancer2025

Therapeutic potential of T-cell receptor targeting the HLA-A*11:01-restricted KRAS

Meiying Shen, Yanan Hao, Xiaxia Han, Bozhi Wang, Luo Li, Tong Chen, Siyin Chen, Lin Zou, Jingjing Huang, Wang Wang and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. HPV-Independent Cervical Cancer-A New Challenge of Modern Oncology.International journal of molecular sciences · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Meiying ShenDepartment of Breast and Thyroid Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Yanan HaoChongqing Key Laboratory of Tumor Immune Regulation and Immune Intervention, Chongqing Medical University, Chongqing, China.
Xiaxia HanChongqing Key Laboratory of Tumor Immune Regulation and Immune Intervention, Chongqing Medical University, Chongqing, China.
Bozhi WangChongqing Key Laboratory of Tumor Immune Regulation and Immune Intervention, Chongqing Medical University, Chongqing, China.
Luo LiChongqing Key Laboratory of Tumor Immune Regulation and Immune Intervention, Chongqing Medical University, Chongqing, China.
Tong ChenChongqing Key Laboratory of Tumor Immune Regulation and Immune Intervention, Chongqing Medical University, Chongqing, China.
Siyin ChenChongqing Key Laboratory of Tumor Immune Regulation and Immune Intervention, Chongqing Medical University, Chongqing, China.
Lin ZouChongqing Key Laboratory of Tumor Immune Regulation and Immune Intervention, Chongqing Medical University, Chongqing, China.
Jingjing HuangChongqing Key Laboratory of Tumor Immune Regulation and Immune Intervention, Chongqing Medical University, Chongqing, China.
Wang WangChongqing Key Laboratory of Tumor Immune Regulation and Immune Intervention, Chongqing Medical University, Chongqing, China.
Shengchun LiuDepartment of Breast and Thyroid Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Xiaojian HanChongqing Key Laboratory of Tumor Immune Regulation and Immune Intervention, Chongqing Medical University, Chongqing, China aishunjin@cqmu.edu.cn xiaojianhan1989@163.com.
Aishun JinDepartment of Breast and Thyroid Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China aishunjin@cqmu.edu.cn xiaojianhan1989@163.com.ORCID http://orcid.org/0000-0001-9746-4220

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPublic neoantigens, including KRAS, TP53, and PIK3CA mutations, which are shared across various tumor types, have demonstrated significant immunogenicity and offer great promise for cancer immunotherapy. Clinical trials targeting these public neoantigens have yielded encouraging results, including tumor regression and prolonged relapse-free survival. This study evaluates the human leukocyte antigen (HLA) binding properties of T-cell epitopes derived from these public neoantigens to identify optimal T-cell target and further develops T-cell receptor (TCR)-based therapeutics.

methodsThe binding properties of public neoantigens to HLA-I molecules were evaluated using peptide-HLA binding affinity and stability assays. Naive T-cell repertoires were used to expand and detect neoantigen-specific TCRs. TCR clones were characterized for functionality using TCR-Jurkat cells and TCR-T cells. Peptide specificity was assessed using an HLA transgenic cell panel and the X-scan assay. In vivo antitumor efficacy of TCR-T cells was tested in xenograft mouse models of solid tumors.

resultsThe analysis of HLA binding properties for public neoantigens revealed that HLA-A*11:01-presented KRAS

conclusionsThese findings highlight significant differences in peptide-HLA binding affinity and stability across public neoantigen-HLA pairings. The cross-recognition of RAB7B

Indexed as

Antigens, NeoplasmHLA-A AntigensNeoplasmsProto-Oncogene Proteins p21(ras)rab GTP-Binding ProteinsReceptors, Antigen, T-CellAnimalsFemaleHumansMicerab7 GTP-Binding ProteinsXenograft Model Antitumor AssaysAntigens, NeoplasmHLA-A AntigensKRAS protein, humanProto-Oncogene Proteins p21(ras)rab7 GTP-Binding Proteinsrab GTP-Binding ProteinsReceptors, Antigen, T-CellHLAImmunotherapyT cellT cell Receptor - TCR

Identifiers

PMID40681176
PMCPMC12278171

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.